What Pediazole Treats: Main Uses and Benefits

Pediazole (erythromycin and sulfisoxazole) is commonly used to help manage conditions associated with susceptible bacteria. It is prescribed to address infections caused by specific types of bacteria, particularly those affecting the middle ear (acute otitis media), respiratory tract, and skin structure. Its primary role is applied across domains where additional symptomatic support is needed.

This medication helps address symptom clusters that may become intense or disruptive, such as fever and acute pain (like earache), which often accompany these conditions presenting with systemic or localized discomfort. By addressing the underlying cause, it contributes to easing the overall symptom load. This supportive relief helps improve day-to-day comfort during periods of heightened symptoms.

The therapeutic benefit supports a more manageable experience, assisting with maintaining functional stability and helping patients cope more steadily with difficult episodes. The medication may assist in easing physical discomfort and supporting management of systemic symptoms like fever.

Quick Fact: Management of Acute Discomfort Pediazole is relevant for easing symptoms related to inflammatory or irritative states, assisting with comfort during acute episodes.

Regulatory References

1. DailyMed indication information from the NIH

Who Can and Cannot Use Pediazole? (Erythromycin/Sulfisoxazole)

The population eligibility for Pediazole is strictly defined by regulatory authorities, with most restrictions relating to the sulfonamide component (Sulfisoxazole).

---

Contraindications and Non-Eligible Populations

Pediazole is strictly contraindicated and must not be used in the following populations:

• Infants less than 2 months of age. This is due to the risk of kernicterus resulting from the sulfonamide component displacing bilirubin from plasma proteins.
• Pregnant women at term. Use is prohibited due to the potential for kernicterus in the newborn.
• Mothers nursing infants less than 2 months of age.
• Patients with a known hypersensitivity to erythromycin, sulfonamides, or any component of the formulation.
• Patients with specific pre-existing conditions, including porphyria, obstructive uropathy, and documented megaloblastic or folate deficiency anemia.

---

Restricted and Approved Use

Approved Population: The medicine is explicitly approved for use in children 2 months of age and older.

Conditional Use: Caution is mandated for patients with impaired hepatic function or impaired renal function as specified in the official labeling. Additionally, use must be with caution in individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency and those with severe allergy or asthma. Pediazole is generally not intended for use in adult patients.

Pediazole, a combination of erythromycin and sulfisoxazole, can interact with a wide range of other medicines, potentially altering the effects of one or both drugs. Discuss all medications and supplements your child is taking with a healthcare professional before starting Pediazole therapy.

---

️ Major Drug Interactions

The erythromycin component can increase the plasma concentrations of certain medicines by inhibiting their metabolism in the liver. This can lead to serious and potentially fatal adverse events. Due to the risk of cardiac arrhythmias (QT prolongation), co-administration is contraindicated with certain drugs, including but not limited to:

• Astemizole (antihistamine)
• Cisapride (prokinetic agent)
• Pimozide (antipsychotic)
• Ergotamine/Dihydroergotamine (migraine medications)

Other Significant Interactions

Close monitoring or dosage adjustment may be required when Pediazole is combined with the following drug classes:

• Anticoagulants (e.g., Warfarin): Sulfisoxazole may enhance the blood-thinning effect, requiring increased monitoring of coagulation time.
• Cholesterol-lowering agents (statins, e.g., Simvastatin, Lovastatin): Increased risk of muscle toxicity (rhabdomyolysis).
• Theophylline (asthma medication): Erythromycin can elevate theophylline levels, increasing the risk of toxicity.
• Seizure medications (e.g., Carbamazepine, Phenytoin): Pediazole may increase serum levels of these drugs.
• Immunosuppressants (e.g., Cyclosporine): Increased concentrations of the immunosuppressant may occur.

---

Food and Products

While Pediazole can be taken with or without food, the sulfisoxazole component may interact with supplements or products that contain para-aminobenzoic acid (PABA), potentially decreasing the antimicrobial efficacy.

The physiological action of Pediazole relies on a dual-target mechanism against susceptible bacteria, resulting in the arrest of bacterial proliferation.

The Erythromycin component, a macrolide, acts by interfering with the cell's machinery for protein assembly. It achieves this by binding non-covalently to the 50S ribosomal subunit inside the bacterial cell. This interaction blocks the bacterial process of translation and peptide elongation, resulting in the cessation of protein assembly. This molecular action contributes to the suppression of bacterial cell growth.

The Sulfisoxazole component, a sulfonamide, targets the metabolic pathway responsible for synthesizing folic acid. As a structural mimic of the precursor PABA, it acts as a competitive inhibitor of the enzyme dihydropteroate synthase (DHPS). By blocking DHPS, the drug prevents the formation of dihydrofolic acid, which in turn depletes the necessary tetrahydrofolate co-factors required for the synthesis of purines and pyrimidines. This lack of precursors arrests the bacteria's ability to replicate.

The synchronized action of stopping essential protein production and preventing the synthesis of genetic material creates a coordinated physiological effect. This dual-pathway blockade arrests bacterial cell proliferation, producing a collective bacteriostatic effect against susceptible organisms.

How Pediazole is Used

Pediazole (erythromycin and sulfisoxazole) is administered exclusively by the oral route as a liquid suspension. The medication is typically supplied as granules that require reconstitution with water to prepare the final liquid dosage form. Following this preparation, the suspension must be shaken well before each use and stored in the refrigerator, with any unused portion designated for discard after 14 days.

Usage protocol is governed by a precise weight-based calculation. The total daily dose for the pediatric population is calculated based on the erythromycin component at 50 mg/kg/day and the sulfisoxazole component at 150 mg/kg/day. This total daily quantity must be administered in equally divided doses three to four times a day (TID or QID) to maintain necessary levels for the full therapeutic period. The administration may occur with or without food, though taking it with food is documented to achieve higher serum concentrations of the active components.

Administration is restricted by age, as the drug is contraindicated in infants less than two months old and is only approved for use in patients who are two months of age or older. Regardless of age, the total treatment period is prescribed as a 10-day course. Throughout the entire course, patients are instructed to maintain adequate fluid intake. Additionally, caution in use is advised for patients with existing hepatic or renal impairment.

Research evidence / Overview of studies for Pediazole

Evidence for Use in Acute Otitis Media (AOM)

The primary research for Pediazole (erythromycin and sulfisoxazole) was evaluated in Randomized Controlled Trials (RCTs) focused on the pediatric population. These studies were set up to explore short-term symptom changes and evaluate the drug combination for Acute Otitis Media (AOM) and recurrent AOM in children, compared against a placebo or other active antibiotics. Research examined outcomes related to physical discomfort, such as ear pain and fever, as well as the status of the middle ear. The core RCT evidence base was established prior to the widespread use of the pneumococcal conjugate vaccine (pre-PCV era), which limits insight into the evidence related to current bacterial strains.

---

Evidence for Other Susceptible Bacterial Infections

In addition to ear infections, Pediazole was studied for use in susceptible bacterial infections of the respiratory tract and skin structure. The research for these conditions often relied on clinical observations and pharmacological studies that examined the two active components. Outcomes related to systemic or functional imbalance were monitored, including measurements of infection signs and the laboratory tracking of the targeted bacteria. However, comparative evidence is lacking, and data for these uses rely more on the known characteristics of the drug classes rather than extensive, dedicated comparative RCTs for the fixed-dose combination.

---

Long-Term Studies and Follow-Up

Studies primarily monitored responses over defined time intervals, with most primary assessments focusing on short-term outcomes over a period of about ten days. While some research explored extended follow-up durations for the prevention of recurrent AOM, there is limited information for long-term outcomes that go beyond the acute phase. Long-term effects are not fully established, particularly concerning any potential long-term impacts on development or functional status years after treatment.

---

What Is Still Uncertain or Remains a Research Gap

Certainty remains low in several areas of the evidence landscape. A significant research limitation is the pre-PCV era context of the core trials; therefore, the results apply only to the specific conditions under which they were conducted. Furthermore, data for certain groups remain insufficient, as the research primarily examined children with Acute Otitis Media. The limited comparative evidence suggests that subgroup findings may be uncertain for other licensed indications.

Key Studies & References

1. Pediazole (Erythromycin Ethylsuccinate and Sulfisoxazole Acetyl) oral suspension label (DailyMed)
2. Erythromycin and Sulfisoxazole Drug Monograph (MedlinePlus)

How to Store and Dispose of Erythromycin and Sulfisoxazole Oral Suspension

The storage and disposal instructions for this oral suspension must strictly adhere to regulatory requirements for stability and safety.

Required Storage Conditions

Condition	Requirement
Temperature	Must be stored in the refrigerator between 2 C and 8 C (36 F and 46 F).
Protection	Must not be frozen. Keep the container tightly closed in its original container.
Stability	Any unused portion of the suspension must be discarded after 14 days of refrigeration.
Child Safety	Store securely out of the sight and reach of children.

Official Disposal Instructions

Unused or expired medicine should be disposed of by using a drug take-back program. If a take-back program is unavailable, the liquid should be mixed with an undesirable substance (such as dirt or coffee grounds), sealed in a plastic bag, and placed in the household trash. The medicine is not on the list for flushing down the toilet or sink.